Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Navigation by reducing the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a Synchrony and SynX Solution offer integrated, real-time information solution to manage, control, record and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including MAGiC catheter, a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures; MAGiC Sweep, a mapping catheter; QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; and V-CAS devices. Further, it provides interventional devices under the Map-iT, MAGiC, and EMAGIN brands, and other related devices. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.…
Global Magnetic Navigation Surgical Robot Market 2026 | Capitalize on 14.1% CAGR Through 2030 as Medtronic, Stereotaxis, Globus Medical, and MicroPort Advance Precision Surgery
Stereotaxis (NYSEAMERICAN: STXS) is listed on NYSE American, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 131 employees.
The shares were at 0.9422 USD on 20 November 2026, down 64.8% over 52 weeks. Its 52-week range is 0.8000 USD to 2.890 USD: the price is 67.4% below the high and 17.8% above the low.
Its market capitalisation is 95.03M USD.
Stereotaxis reports return on equity of -115.6%, an operating margin of -65.4% and revenue up 19.6% year over year.
Its debt exceeds its cash by 3.93M USD, a debt-to-equity ratio of 0.29. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 2.667 USD is 183.0% above the current price. The next earnings report is expected on 8 March 2027.